| Ytd | -12.06% | |
| 1y | 5.20% |
| Open | 11.81 | Prev Close | 11.89 | Low | 11.65 | High | 11.93 | Mkt Cap | 312.08M |
| Vol | 10.22K | Avg Vol | 111.29K | EPS | -1.14 | P/E | -10.43 | Forward P/E | -1.23 |
| Beta | 0.25 | Short Ratio | 1.35 | Inst. Own | 82.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 11.95 | 200-d Avg | 12.47 | 1yr Est | 25.43 |
BNTC News
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-u
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec”
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-tre
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L b
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L p
The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Be
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) Director Suvretta Capital Management, L b
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the st
Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of t
– Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) re
In the past week or so, beneficial owners Carl Icahn and Mario Gabelli made some big bets in Monro I
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec”
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec”
HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec”
Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST Investor webcast to be held on
Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) has been assigned an average rating of "M
Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 12
During Wednesday's trading, 517 companies set new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 216 stocks hit new 52-week lows.
Tuesday's session saw 211 companies set new 52-week lows.